NeuroScientific Biopharmaceuticals says it has secured a key meeting with the US Food and Drug Administration (FDA) for its StemSmart technology, which it plans to test in a Phase 2 trial for refractory Crohn’s disease.
One outlet describes the engagement as an FDA meeting tied to the planned Phase 2 study, while another specifies it as a Pre-IND meeting scheduled for Aug. 31. All reports frame the technology as intended for use in the US and focus on regulatory engagement ahead of the company’s clinical development plans.
The coverage is largely consistent across outlets, with differences mainly in the level of detail provided about the meeting type and timing rather than the underlying purpose of the FDA discussion or the disease indication. The company’s stated goal is to progress its development pathway for StemSmart for patients with refractory Crohn’s disease through the next planned trial phase.
